JP2012506402A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506402A5
JP2012506402A5 JP2011532609A JP2011532609A JP2012506402A5 JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5 JP 2011532609 A JP2011532609 A JP 2011532609A JP 2011532609 A JP2011532609 A JP 2011532609A JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5
Authority
JP
Japan
Prior art keywords
pramlintide
carboxy
carboxynonadecanoylamino
butyryl
his17
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532609A
Other languages
English (en)
Japanese (ja)
Other versions
JP5703226B2 (ja
JP2012506402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/063724 external-priority patent/WO2010046357A1/en
Publication of JP2012506402A publication Critical patent/JP2012506402A/ja
Publication of JP2012506402A5 publication Critical patent/JP2012506402A5/ja
Application granted granted Critical
Publication of JP5703226B2 publication Critical patent/JP5703226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532609A 2008-10-21 2009-10-20 アミリン誘導体 Active JP5703226B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08167154.7 2008-10-21
EP08167154 2008-10-21
EP09161372 2009-05-28
EP09161372.9 2009-05-28
PCT/EP2009/063724 WO2010046357A1 (en) 2008-10-21 2009-10-20 Amylin derivatives

Publications (3)

Publication Number Publication Date
JP2012506402A JP2012506402A (ja) 2012-03-15
JP2012506402A5 true JP2012506402A5 (enExample) 2012-12-06
JP5703226B2 JP5703226B2 (ja) 2015-04-15

Family

ID=41728511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532609A Active JP5703226B2 (ja) 2008-10-21 2009-10-20 アミリン誘導体

Country Status (7)

Country Link
US (1) US8895504B2 (enExample)
EP (1) EP2340261B1 (enExample)
JP (1) JP5703226B2 (enExample)
CN (1) CN102197049B (enExample)
ES (1) ES2662501T3 (enExample)
TW (1) TW201018479A (enExample)
WO (1) WO2010046357A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
WO2012168430A2 (en) * 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
EP2838914B1 (en) 2012-04-19 2017-06-14 Novo Nordisk A/S Human amylin analogues
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
CN107567459B (zh) 2015-03-18 2021-09-24 西兰制药公司 胰淀素类似物
CN106554405B (zh) * 2015-09-30 2020-04-24 深圳翰宇药业股份有限公司 一种多肽及其用途、制备方法
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
IL282079B2 (en) 2018-10-11 2025-09-01 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
WO2020225781A1 (en) * 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
IL303578A (en) 2020-12-16 2023-08-01 Medimmune Ltd Polypeptides and their uses
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
GB202217575D0 (en) * 2022-11-24 2023-01-11 Imperial College Innovations Ltd Novel compounds
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
WO2026046286A1 (zh) * 2024-08-29 2026-03-05 杭州九源基因生物医药股份有限公司 一种人胰淀素类似物及其衍生物与医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5710024A (en) 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
US20040022807A1 (en) 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
NZ534557A (en) 2002-01-08 2007-10-26 Amylin Pharmaceuticals Inc Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
EP1954313A1 (en) 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007104789A2 (en) * 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives

Similar Documents

Publication Publication Date Title
JP2012506402A5 (enExample)
CN114901682B (zh) 胰岛素衍生物
US9382304B2 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2008533105A5 (enExample)
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
JP5969461B2 (ja) Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
JP2013523618A5 (enExample)
US20150133373A1 (en) Transmucosal delivery of engineered polypeptides
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2014516049A5 (enExample)
JP2014519509A5 (enExample)
RU2020136305A (ru) Производные gip и пути их применения
JP2013543853A5 (enExample)
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2014519511A5 (enExample)
JP2011524420A5 (enExample)
JP2013523619A5 (enExample)
RU2013156937A (ru) Полипептиды
JP2014519510A5 (enExample)
JP2010538049A5 (enExample)
US20140256621A1 (en) Engineered poypeptides having enhanced duration of action and reduced immunogenicity
JP2012529463A (ja) 2型糖尿病を治療するための、glp−1とfgf21との組合せ
JP2012512903A5 (enExample)
MX2013001131A (es) Compuestos agonistas del receptor del peptido similar al glucagon tipo 1 que tienen regiones estabilizadas.
JP2017536343A5 (enExample)